Recent News

• 11.04.2026 - Insmed to Present at November and December 2026 Investor Conferences
• 10.29.2026 - Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
• 10.20.2026 - Insmed Appoints Two New Directors to Its Board
• 10.19.2026 - Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
• 10.15.2026 - Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
• 10.14.2026 - Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
• 10.05.2026 - Insmed Announces CFO Transition
• 09.21.2026 - FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
• 09.16.2026 - Insmed Expands Community Impact During Fifth Annual Global Day of Good
• 09.04.2026 - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Recent Filings

• 11.03.2026 - 144 Report of proposed sale of securities
• 11.03.2026 - 3 Initial statement of beneficial ownership of securities
• 10.29.2026 - 8-K Current report
• 10.29.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.29.2026 - EX-99.1 EX-99.1
• 10.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2026 - 3 Initial statement of beneficial ownership of securities
• 10.20.2026 - 3 Initial statement of beneficial ownership of securities
• 10.20.2026 - 8-K Current report